Phase I trial of docetaxel plus lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (177Lu-J591) for metastatic castration-resistant prostate cancer.
CONCLUSION: The combination of 177Lu-J591 delivered as a single fractionated cycle with docetaxel/prednisone is feasible in patients with mCRPC. Without preselection for prostate-specific membrane antigen, accurate targeting of known sites of disease and a strong preliminary efficacy signal was observed.
PMID: 32600929 [PubMed - as supplied by publisher]
Source: Urologic Oncology - Category: Urology & Nephrology Authors: Batra JS, Niaz MJ, Whang YE, Sheikh A, Thomas C, Christos P, Vallabhajosula S, Jhanwar YS, Molina AM, Nanus DM, Osborne J, Bander NH, Tagawa ST Tags: Urol Oncol Source Type: research
More News: Cancer | Cancer & Oncology | CT Scan | Docetaxel | Hematology | PET Scan | Prednisone | Prostate Cancer | Study | Taxotere | Toxicology | Urology & Nephrology